KIMBERLY MCHUGH: Open Payments
NPI 1750770772 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,082 in 53 payments from 14 companies in 2025. Trend: 2023 $826 · 2024 $799 · 2025 $1,082
Food & beverage: $983Education: $99
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 18 | $353 |
| Insmed, Inc. | 10 | $138 |
| Actelion Pharmaceuticals US, Inc. | 2 | $127 |
| Verona Pharma, Inc. | 4 | $89 |
| GENZYME CORPORATION | 4 | $77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $52 |
| Vifor Pharma, Inc. | 2 | $48 |
| PFIZER INC. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
Products named: TRELEGY ELLIPTA, Arikayce, OPSUMIT, DUPIXENT, NUCALA, Ohtuvayre, OFEV, Zemaira.
Industry payments across TX — which companies pay providers there.
